Ghent University Academic Bibliography

Advanced

Ischemic stroke and hyperhomocysteinemia: truth or myth?

ANNELIES TERWECOREN UGent, ELKE STEEN UGent, Dominique Benoit UGent, Paul Boon UGent and Dimitri Hemelsoet UGent (2009) ACTA NEUROLOGICA BELGICA. 109(3). p.181-188
abstract
Hyperhomocysteinemia is generally acknowledged as a treatable risk factor for atherotrombotic diseases, but a causal relationship between both is not Yet definitively established. Hyperhomocysteinemia originates from a deviation in the methionine-homocysteine metabolism including disturbances of enzymes, vitamin deficiencies and different other factors. Observational studies, genetic polymorphism studies and several meta-analyses implicate already a causal relation between homocysteine and cerebrovascular diseases. It is useful to determine homocysteine levels for stroke who present no clue for vascular disease and thrombosis, who have an ischemic stroke at a young age and who have a family history of premature atherosclerosis. Because of the low cost and safety of the therapy, the American Heart and Stroke Association advises to treat patients with a stroke and hyperhomocysteinemia daily with 0,4 mg folic acid, 2,4 mu g vitamin 1312 and 1, 7 mg vitamin B6. A significant benefit in secondary prevention is not yet proven. The results of larger follow-up trials have to be published.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
VITAMIN INTERVENTION, EFFICACY ANALYSIS, PREVENTION TRIAL, CARDIOVASCULAR EVENTS, MYOCARDIAL-INFARCTION, RANDOMIZED CONTROLLED-TRIAL, vitamin therapy, secondary prevention, ischemic stroke, methionine-homocysteine metabolism, Hyperhomocysteinemia, RISK, FOLIC-ACID, HOMOCYSTEINE, DISEASE
journal title
ACTA NEUROLOGICA BELGICA
Acta Neurol. Belg.
volume
109
issue
3
pages
8 pages
Web of Science type
Review
Web of Science id
000271097700003
JCR category
CLINICAL NEUROLOGY
JCR impact factor
0.597 (2009)
JCR rank
147/165 (2009)
JCR quartile
4 (2009)
ISSN
0300-9009
language
English
UGent publication?
yes
classification
A1
id
829160
handle
http://hdl.handle.net/1854/LU-829160
date created
2010-01-18 09:52:43
date last changed
2010-04-26 17:22:22
@article{829160,
  abstract     = {Hyperhomocysteinemia is generally acknowledged as a treatable risk factor for atherotrombotic diseases, but a causal relationship between both is not Yet definitively established. Hyperhomocysteinemia originates from a deviation in the methionine-homocysteine metabolism including disturbances of enzymes, vitamin deficiencies and different other factors. Observational studies, genetic polymorphism studies and several meta-analyses implicate already a causal relation between homocysteine and cerebrovascular diseases.
It is useful to determine homocysteine levels for stroke who present no clue for vascular disease and thrombosis, who have an ischemic stroke at a young age and who have a family history of premature atherosclerosis. Because of the low cost and safety of the therapy, the American Heart and Stroke Association advises to treat patients with a stroke and hyperhomocysteinemia daily with 0,4 mg folic acid, 2,4 mu g vitamin 1312 and 1, 7 mg vitamin B6. A significant benefit in secondary prevention is not yet proven. The results of larger follow-up trials have to be published.},
  author       = {TERWECOREN, ANNELIES and STEEN, ELKE and Benoit, Dominique and Boon, Paul and Hemelsoet, Dimitri},
  issn         = {0300-9009},
  journal      = {ACTA NEUROLOGICA BELGICA},
  keyword      = {VITAMIN INTERVENTION,EFFICACY ANALYSIS,PREVENTION TRIAL,CARDIOVASCULAR EVENTS,MYOCARDIAL-INFARCTION,RANDOMIZED CONTROLLED-TRIAL,vitamin therapy,secondary prevention,ischemic stroke,methionine-homocysteine metabolism,Hyperhomocysteinemia,RISK,FOLIC-ACID,HOMOCYSTEINE,DISEASE},
  language     = {eng},
  number       = {3},
  pages        = {181--188},
  title        = {Ischemic stroke and hyperhomocysteinemia: truth or myth?},
  volume       = {109},
  year         = {2009},
}

Chicago
TERWECOREN, ANNELIES, ELKE STEEN, Dominique Benoit, Paul Boon, and Dimitri Hemelsoet. 2009. “Ischemic Stroke and Hyperhomocysteinemia: Truth or Myth?” Acta Neurologica Belgica 109 (3): 181–188.
APA
TERWECOREN, A., STEEN, E., Benoit, D., Boon, P., & Hemelsoet, D. (2009). Ischemic stroke and hyperhomocysteinemia: truth or myth? ACTA NEUROLOGICA BELGICA, 109(3), 181–188.
Vancouver
1.
TERWECOREN A, STEEN E, Benoit D, Boon P, Hemelsoet D. Ischemic stroke and hyperhomocysteinemia: truth or myth? ACTA NEUROLOGICA BELGICA. 2009;109(3):181–8.
MLA
TERWECOREN, ANNELIES, ELKE STEEN, Dominique Benoit, et al. “Ischemic Stroke and Hyperhomocysteinemia: Truth or Myth?” ACTA NEUROLOGICA BELGICA 109.3 (2009): 181–188. Print.